&xA0;
Sacbee.com is happy to provide a forum for reader interaction, discussion, feedback and reaction to our stories. However, we reserve the right to delete inappropriate comments or ban users who cant play nice. (See our full terms of service here.)
&149; Do not use the commenting system for advertising. Thats spam and it isnt allowed.
The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nations food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.
What You Should Know About Comments on Sacbee.com
FDA Approves Inlyta To Treat Patients With a Type of Advanced Kidney Cancer? hypertension treatment,Drug helps keep cancer from progressing
If you submit a comment, the user name of your account will appear along with it. Users cannot remove their own comments once they have submitted them.
Recently approved drugs for the treatment of kidney cancer include sorafenib (2005), sunitinib (2006), temsirolimus (2007), everolimus (2009), bevacizumab (2009) and pazopanib (2009).
scsharelinkb background: url( no-repeat left center; padding-left: 20
&xA0; &xA0;
This section contains unedited press releases distributed by PR Newswire.These releases reflect the views of the issuing entity and are not reviewed or edited by the Sacramento Bee staff. More information on PR Newswire can be found on theirweb site. You can contact the service with questions or concernshere.
The safety and effectiveness of Inlyta were evaluated in a single randomized, open-label, multi-center clinical study of 723 patients whose disease had progressed on or after treatment with one prior systemic therapy. The study was designed to measure progression-free survival, the time a patient lived without the cancer progressing. Results showed a median progression-free survival of 6.7 months compared to 4.7 months with a standard treatment (sorafenib).
Patients with high blood pressure should have it well-controlled before taking Inlyta. Some patients who took Inlyta experienced bleeding problems, which in some cases were tal. Patients with untreated brain tumors or gastrointestinal bleeding should not take Inlyta.
&149; Stay on topic. Only post comments relevant to the article at hand.
(Logo:
This is the seventh drug that has been approved for the treatment of metastatic or advanced kidney cell cancer since 2005, said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDAs Center for Drug Evaluation and Research. Collectively, this unprecedented level of drug development within this time period has significantly altered the treatment paradigm of metastatic kidney cancer, and offers patients multiple treatment options.
&149; Dont use all capital letters. Thats akin to yelling and not appreciated by the audience.
SOURCE U.S. Food and Drug Administration
&149; Do not attack other users; focus your comments on issues, not individuals.
&149; Keep your comments civil. Dont insult one another or the subjects of our articles. If you think a comment violates our guidelines click the Report Abuse link to notify the moderators. Responding to the comment will only encourage bad behavior.
&149; Dont repeat the same comment over and over. We heard you the first time.
mi_top_job jobstreamwidth:280px !importantmi_top_job jobstreamrelative;-19mi_top_job .headerwidth:270px !importantmi_top_job mi_top_job_more0mi_top_job jobstream div formdisplay:nonemi_top_job jobstream div td 1px solid CCCCCC; 2px:line-1.3em;0mi_top_job jobstFDA Approves Inlyta To Treat Patients With a Type of Advanced Kidney Cancer? hypertension treatmentream imgdisplay:nonedivjobsmargin-bottom:13divjobs .hypertension treatmentrailunitmargin-bottom:0div.block divcb-topjobs padding-bottom:0px !important;0px !importantdiv.careerbuilderoverflow:hidden !important
Reader comments on Sacbee.com are the opinions of the writer, not The Sacramento Bee. If you see an objectionable comment, click the Report Abuse link below it. We will delete comments containing inappropriate links, obscenities, hate speech, and personal attacks. Flagrant or repeat violators will be banned.See more about comments here.
&149; Dont use pronities, vulgarities or hate speech. This is a general interest news site. Sometimes, there are children present. Dont say anything in a way you wouldnt want your own child to hear.
SILVER SPRING, Md., Jan. 27, 2012 /PRNewswire-USNewswire/ --&xA0;The U.S. Food and Drug Administration today approved Inlyta (axitinib) to treat patients with advanced kidney cancer (renal cell carcinoma) who have not responded to another drug for this type of cancer.
Renal cell carcinoma is a type of kidney cancer that starts in the lining of very small tubes in the kidney. Inlyta works by blocking certain proteins called kinases that play a role in tumor growth and cancer progression. Inlyta is a pill that patients take twice a day.
The most common side effects observed in greater than 20 percent of patients in the clinical study were diarrhea, high blood pressure (hypertension), tigue, decreased appetite, nausea, loss of voice (dysphonia), hand-foot syndrome (palmar-plantar erythrodysesthesia), weight loss, vomiting, weakness (asthenia) and constipation.
Inlyta is marketed by New York City-based Pfizer Inc.
FDA: Office of Hematology and Oncology Products
&149; Do not copy and paste outside material into the comment box.
&149; Dont flag other users comments just because you dont agree with their point of view. Please only flag comments that violate these guidelines.
Media Inquiries:Stephanie Yao, 301-796-0394,[email protected] Inquiries:888-INFO-FDA
You should also know that The Sacramento Bee does not screen comments before they are posted. You are more likely to see inappropriate comments before our staff does, so we ask that you click the Report Abuse link to submit those comments for moderator review. You also may notify us via email [email protected]. Note the headline on which the comment is made and tell us the profile name of the user who made the comment. Remember, comment moderation is subjective. You may find some material objectionable that we wont and vice versa.
About Comments
FDA: Approved Drugs: Questions and Answers
Here are some rules of the road:
For more information:
